Financials data is unavailable for this security.
View more
Year on year Nxera Pharma Co Ltd 's revenues fell -18.00% from 15.57bn to 12.77bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 382.00m to a loss of 7.19bn.
| Gross margin | 72.71% |
|---|---|
| Net profit margin | -42.14% |
| Operating margin | -38.61% |
| Return on assets | -7.55% |
|---|---|
| Return on equity | -14.94% |
| Return on investment | -8.18% |
More ▼
Cash flow in JPYView more
In 2023, cash reserves at Nxera Pharma Co Ltd fell by 17.49bn. Cash Flow from Financing totalled 48.33bn or 378.58% of revenues. In addition the company used 5.27bn for operations while cash used for investing totalled 63.79bn.
| Cash flow per share | -70.48 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 767.28 |
|---|---|
| Tangible book value per share | -104.29 |
More ▼
Balance sheet in JPYView more
| Current ratio | 4.11 |
|---|---|
| Quick ratio | 3.96 |
| Total debt/total equity | 1.03 |
|---|---|
| Total debt/total capital | 0.5075 |
More ▼
Growth rates in JPY
SmartText is unavailable
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -647.81 |
